Ascendis Pharma A/S - Share Repurchase Program Update
15 nov. 2021 08h00 HE
|
Ascendis Pharma
COPENHAGEN, Denmark, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided an update on the Company’s previously announced $25 million American Depositary Shares (ADS)...
Ascendis Pharma A/S Receives Positive CHMP Opinion for TransCon™ hGH for Patients with Pediatric Growth Hormone Deficiency
12 nov. 2021 07h22 HE
|
Ascendis Pharma
– TransCon hGH is a once-weekly prodrug of somatropin designed to reduce the treatment burden for patients with growth hormone deficiency. – Final European Commission decision on TransCon hGH MAA...
Ascendis Pharma A/S Reports Third Quarter 2021 Financial Results
10 nov. 2021 16h01 HE
|
Ascendis Pharma
– SKYTROFA® (lonapegsomatropin-tcgd) approved by the FDA in the U.S. as a once-weekly treatment for pediatric growth hormone deficiency (GHD); commercially launched in October 2021. – Completed...
Ascendis Pharma A/S Presents New Non-Clinical Data for TransCon™ TLR7/8 Agonist Oncology Program at SITC 2021
09 nov. 2021 08h00 HE
|
Ascendis Pharma
- In non-clinical models, a single dose of TransCon™ TLR7/8 Agonist activated critical innate and adaptive immune mechanisms, providing sustained modulation of tumor microenvironments with low...
Ascendis Pharma A/S - Share Repurchase Program Update
08 nov. 2021 08h00 HE
|
Ascendis Pharma
COPENHAGEN, Denmark, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided an update on the Company’s previously announced $25 million American Depositary Shares (ADS)...
Ascendis Pharma A/S Announces Third Quarter 2021 Financial Results and Business Update Conference Call on November 10
03 nov. 2021 08h00 HE
|
Ascendis Pharma
COPENHAGEN, Denmark, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today announced that the Company will hold a conference call and live webcast on Wednesday, November 10,...
Ascendis Pharma A/S Announces U.S. Commercial Launch of SKYTROFA® (Lonapegsomatropin-tcgd), the First and Only FDA Approved Once-Weekly Treatment for Pediatric Growth Hormone Deficiency
15 oct. 2021 08h00 HE
|
Ascendis Pharma
COPENHAGEN, Denmark, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today announced the U.S. commercial launch of SKYTROFA (lonapegsomatropin-tcgd), its once-weekly treatment...
Ascendis Pharma A/S Announces Presentations for TransCon™ PTH and TransCon™ CNP at the American Society for Bone & Mineral Research 2021 Annual Meeting
30 sept. 2021 16h01 HE
|
Ascendis Pharma
– Late-breaking oral presentation will feature a comprehensive review of 58-week results from the company’s Phase 2 PaTH Forward Trial – COPENHAGEN, Denmark, Sept. 30, 2021 (GLOBE NEWSWIRE)...
Ascendis Pharma A/S Announces Share Repurchase Program
29 sept. 2021 16h01 HE
|
Ascendis Pharma
COPENHAGEN, Denmark, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new...
Ascendis Pharma A/S Announces Mean Bone Mineral Density (BMD) Data from Phase 2 PaTH Forward Trial Demonstrating Continued Normalization and Stabilization of BMD Z-scores Between 26 and 58 Weeks
22 sept. 2021 16h27 HE
|
Ascendis Pharma
– Data from subjects with available dual energy x-ray absorptiometry (DXA) scans demonstrated stabilization of BMD, in alignment with observed bone turnover markers previously reported – COPENHAGEN,...